HIGHLIGHTS
- who: TYPE et al. from the Shandong University, China have published the Article: Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland, in the Journal: (JOURNAL)
- what: This study aimed to compare the oncological outcome measures and evaluate prognostic factors affecting survival in real-life populations of patients treated with ABI and ENZA in Poland.
- how: The analyzed data were obtained from the Polish National Health Fund Drug Program database. The study was conducted on all subsequent patients from these centers who met . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.